Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms (Psilodep-RCT)

NCT03429075 PHASE2 COMPLETED Results posted

This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor (SSRI) escitalopram for major depressive disorder (MDD).

Details

Lead sponsor	Imperial College London
Phase	PHASE2
Status	COMPLETED
Enrolment	59
Start date	Mon Jan 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Oct 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Depressive Disorder, Major

Interventions

• Psilocybin + Placebo
• Psilocybin + Escitalopram

Countries

United Kingdom